Browse Studies — Arctuva

Phase 3

Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, there…

Neoplasms, Lung

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07099898

Phase 1

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors

This is an early-phase clinical study investigating a new combination treatment, Risvutatug rezetecan (Ris-Rez) given with ivonescimab for adults with advanced…

Neoplasms, Lung

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT07602855

Phase 1

A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalat…

Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma

Estimated

~$10 – $8,750

MediLink Therapeutics (Suzhou) Co., Ltd.NCT07407933

Observational

Precision Lung Cancer Survivorship Care Intervention: A Randomized Controlled Trial Serving Rural Survivors and Communities

The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative…

Lung CancerPulmonary NeoplasmNeoplasms, Lung+12 more

Estimated

~$10 – $7,500

Jerod L Stapleton, PhDNCT05857995